Russian sovereign fund RDIF said on Friday it has achieved positive results from a small-scale study into the combined use of the AstraZeneca vaccine and the first component of the Sputnik V vaccine.
“Preliminary data from the first 20 participants shows antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases,” RDIF said in a statement, citing a clinical trial carried out together with AstraZeneca in Azerbaijan.
